CDT Equity (CDT) Accumulated Expenses (2021 - 2026)
CDT Equity's (CDT) quarterly Accumulated Expenses came in at $9.6 million in Q1 2026, up 119900.0% YoY from N/an in Q1 2025, and little changed on a QoQ basis from $9.6 million in Q4 2025.
CDT Equity (CDT) Accumulated Expenses (2021 - 2026) Analysis & Trends
CDT Equity (CDT) has 6 years of Accumulated Expenses data on file, last reported at $9.6 million in Q1 2026.
- Quarterly Accumulated Expenses rose 119900.0% year-over-year to $9.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.6 million (up 119900.0% YoY) and the FY2025 annual result came in at $9.6 million, up 2300.0% from the prior year.
- Accumulated Expenses was little changed at $9.6 million in Q1 2026, from $9.6 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $9.6 million in Q4 2025 to a low of $8000.0 in Q1 2025.
- A 5-year average of $1.4 million and a median of $227500.0 in 2024 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2025 — Accumulated Expenses plunged 96.89% — and 2026, when it soared 119900.0%.
- Tracing CDT's Accumulated Expenses over 5 years: stood at $338000.0 in 2022, then sank by 70.41% to $100000.0 in 2023, then jumped by 300.0% to $400000.0 in 2024, then soared by 2300.0% to $9.6 million in 2025, then changed by 0.0% to $9.6 million in 2026.
- The last three Accumulated Expenses figures came in at $9.6 million (Q1 2026), $9.6 million (Q4 2025), and $14000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | CDT Equity | 1.55 Mn | 1.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.60 Mn |
| Mar 31, 2026 | 9.60 Mn |
| Dec 31, 2025 | 9.60 Mn |
| Sep 30, 2025 | 14,000.00 |
| Jun 30, 2025 | 9,000.00 |
| Mar 31, 2025 | 8,000.00 |
| Dec 31, 2024 | 400,000.00 |
| Sep 30, 2024 | 443,000.00 |
| Jun 30, 2024 | 289,000.00 |
| Mar 31, 2024 | 166,000.00 |
| Dec 31, 2023 | 100,000.00 |
| Sep 30, 2023 | 33,000.00 |
| Jun 30, 2023 | 24,528.00 |
| Mar 31, 2023 | 1.43 Mn |
| Dec 31, 2022 | 338,000.00 |
| Sep 30, 2022 | 316,128.00 |
| Jun 30, 2022 | 138,645.00 |
| Dec 31, 2021 | 15,449.00 |